Leadership: Page 9
-
Q&A // First 90 Days
Brian Fox is bringing ‘fresh eyes’ to ad agency Klick
Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.
By Karissa Waddick • Feb. 13, 2023 -
Making Moves
Bayer, Astellas switch CEOs amid major inflection points
Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.
By Karissa Waddick • Feb. 9, 2023 -
Trendline
Clinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Podcast
Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye
The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.
By Taren Grom • Feb. 8, 2023 -
Profile
The unique playbook of Biohaven’s CEO
Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?
By Meagan Parrish • Feb. 8, 2023 -
Q&A // First 90 Days
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
By Kelly Bilodeau • Feb. 6, 2023 -
Making Moves
Roche, Chiesi and the FDA change major leadership roles as they strive for growth in 2023
From Roche’s new pharma chief to the departure of the FDA’s gene therapy head, these moves are bound to shake up the industry.
By Karissa Waddick • Feb. 6, 2023 -
Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma
A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.
By Michael Gibney • Feb. 2, 2023 -
Podcast
Woman of the Week: Bayer’s Dr. Yesmean Wahdan
The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.
By Taren Grom • Feb. 1, 2023 -
Q&A
This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
By Michael Gibney • Jan. 31, 2023 -
Q&A
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
By Meagan Parrish • Jan. 26, 2023 -
Podcast
Woman of the Week: Dr. Lauren Lazar
As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.
By Taren Grom • Jan. 25, 2023 -
Economic crisis? J&J execs say that won’t stop them from hitting $60B target
The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.
By Michael Gibney • Jan. 25, 2023 -
Podcast
Woman of the Week: Genetika+’s Talia Cohen Solal
The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.
By Taren Grom • Jan. 18, 2023 -
Biopharma M&A may get the push it needs in 2023, but with a face lift
A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.
By Michael Gibney • Jan. 12, 2023 -
Biotech Spotlight
Chinook Therapeutics nears the finish line in kidney disease
A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.
By Michael Gibney • Jan. 10, 2023 -
Making Moves
C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans
A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.
By Karissa Waddick • Jan. 10, 2023 -
The kindred nature of martial arts and drug development
How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.
By Alexandra Pecci • Jan. 9, 2023 -
What’s top of mind for industry execs at JPM?
Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.
By Taren Grom • Jan. 6, 2023 -
Podcast
Woman of the Week: Cambrian BioPharma’s Juliette Han
The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.
By Taren Grom • Jan. 4, 2023 -
Profile
Forks in the road lead one medical expert to a ‘game changing’ liver treatment
Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.
By Alexandra Pecci • Jan. 3, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
From chemistry to canvas: What the pharma world can learn from art
Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work.
By Karissa Waddick • Dec. 22, 2022 -
Opinion
WoW: What a year
A look back at some of the most inspirational quotes from the Women of the Week podcasts in 2022.
By Taren Grom • Dec. 20, 2022 -
Blood cancer cures aren’t here yet — but incremental combinations bring the field closer
A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.
By Michael Gibney • Dec. 19, 2022 -
Profile
How one of the world’s most prolific inventors is guiding a plan to tackle all disease
Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.
By Alexandra Pecci • Dec. 15, 2022